Form 4: Dyne Therapeutics Executive Jonathan McNeill Sells Shares to Cover Tax Obligations

Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On August 19, 2024, Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, sold 2,400 shares of common stock at a weighted average price of $45.01 and 305 shares at a weighted average price of $46.
• The sales were executed automatically to satisfy tax withholding obligations related to the vesting of restricted stock units granted on November 15, 2023.
• These sales were conducted under a pre-arranged plan (Rule 10b5-1) established on January 25, 2024.
• Following the transactions, McNeill directly owns 132,106 shares of Dyne Therapeutics, which includes 116,875 unvested RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a routine transaction related to tax obligations. It doesn't indicate any fundamental change in the company's prospects or management's confidence.

Industry Context

Sales of shares by company executives are a common occurrence, often related to compensation and tax obligations. The use of a pre-arranged Rule 10b5-1 plan indicates that the sales were planned in advance and not based on insider information.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but the pre-planned nature of the sale and its purpose (tax obligations) mitigate any significant negative perception.

Key Dates